VANCOUVER, BC, November 9, 2021 – PanGenomic Health Corp. (the “Company” or “PanGenomic Health”) is pleased to announce that its shareholders have approved the sale of all of the issued and outstanding shares of the Company to Zetta Capital Corp. (“Zetta Capital”) of Vancouver, BC in a share exchange transaction.
PanGenomic Health is developing a precision health platform that delivers personalized, evidence-based information about natural treatments to support mental health. The Company’s products under development include a mobile app for consumers and a digital therapeutics clinic platform for health practitioners.
“We are excited to accelerate our business with the funding and capital market support brought by the team at Zetta Capital”, said Vincent Lum, CEO of PanGenomic Health. “In a time of tremendous mental health challenges for people all over the world, PanGenomic Health’s platform will empower individuals with knowledge about plant medicine options personalized to their genomic and proteomic health profiles.”
PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments to support mental health. The Company’s mission is to improve the health and wellness of people by providing a technology platform that identifies natural treatments tailored to the health profile of each individual.
On behalf of PanGenomic Health Corp.
Vincent Lum, CEO
This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risk that the anticipated benefits of the transaction will be realized as contemplated, or at all, risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. The statements in this news release are made as of the date of this release.